Cosentyx (secukinumab) For The Treatment of Plaque Psoriasis
A new prescription medication, Cosentyx (also known as secukinumab), has been passed by the FDA for the treatment of moderate-to-severe plaque psoriasis. Psoriasis is an immune-mediated disorder that has a number of manifestations on the skin and in the body. “Plaque Psoriasis is the most common form of psoriasis, that presents with pink, scaly plaques on the knees, elbows, scalp, lower back and other areas,” says Dr. Adam Mamelak, a board-certified Dermatologist at Sanova Dermatology in Austin, Texas. “This disease can really take a toll on those affected, which makes finding good treatment options so crucial.”
Cosentyx is a biologic medication that blocks a very specific protein in the body. This protein, known as a cytokine, is intimately involved stimulating and maintaining the inflammation that leads to the development of Psoriasis skin disease. This specific cytokine is called interleukin17-A, which has been noted in high levels in those individuals who suffer from plaque psoriasis. “By blocking this protein, this medication is able to disrupt the inflammatory cycle before it has the chance to cause plaques on the skin,” says Dr. Mamelak. The result is a significant decrease in skin lesions and ultimately, clear skin. The medication is injected under the skin, like other biologic medications for psoriasis.
For more information about Cosentyx or other forms of Psoriasis treatment, please contact us today. Our physicians have the knowledge, skill and compassion to help you with all of your skin care needs.